Exploring Europe's Undiscovered Stock Gems This October 2026
As the European market navigates a landscape marked by improving growth indicators and inflationary pressures, small-cap stocks have shown mixed performance amid fluctuating economic conditions. With indices like the STOXX Europe 600 seeing modest gains, investors are increasingly looking for promising opportunities in under-the-radar companies that can offer resilience and potential growth. In this context, identifying stocks with strong fundamentals and innovative strategies becomes crucial for those seeking to capitalize on Europe's evolving market dynamics.
Top 10 Undiscovered Gems With Strong Fundamentals In Europe
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Apator | 13.65% | 6.21% | 20.01% | ★★★★★★ |
| B&C Speakers | 39.08% | 14.82% | 13.88% | ★★★★★★ |
| C-Rad | NA | 13.57% | 13.83% | ★★★★★★ |
| Angler Gaming | NA | -4.50% | -4.71% | ★★★★★★ |
| innoscripta | 30.37% | 42.47% | 38.04% | ★★★★★☆ |
| Edel SE KGaA | 142.35% | 1.36% | 12.24% | ★★★★☆☆ |
| Skue Sparebank | 122.31% | 16.16% | 27.93% | ★★★★☆☆ |
| SP Group | 83.41% | 5.40% | 9.36% | ★★★★☆☆ |
| Lea Bank | 9.61% | -9.44% | -36.79% | ★★★★☆☆ |
| Aqualis | 33.30% | 22.28% | -18.13% | ★★★☆☆☆ |
Here we highlight a subset of our preferred stocks from the screener.
Sparebanken Møre (OB:MORG)
Simply Wall St Value Rating: ★★★★☆☆
Overview: Sparebanken Møre, along with its subsidiaries, offers banking services to both retail and business sectors in Norway and has a market capitalization of NOK5.40 billion.
Operations: Sparebanken Møre generates revenue primarily from its retail and corporate banking segments, with contributions of NOK1.03 billion and NOK839 million, respectively. The real estate brokerage segment adds a smaller portion with NOK42 million.
Sparebanken Møre, with total assets of NOK112.6 billion and equity of NOK9.1 billion, stands out for its robust financial health despite being a smaller player in the banking sector. Total loans amount to NOK93.9 billion against deposits of NOK53.7 billion, reflecting a strategic balance between lending and funding sources, primarily low-risk customer deposits at 52% of liabilities. The bank's earnings growth rate is commendable at 6.6%, outpacing the industry average by a significant margin and indicating strong operational performance. However, it faces challenges with an insufficient allowance for bad loans at 1.2% of total loans, suggesting room for improvement in risk management practices.
- Dive into the specifics of Sparebanken Møre here with our thorough health report.
Examine Sparebanken Møre's past performance report to understand how it has performed in the past.
RaySearch Laboratories (OM:RAY B)
Simply Wall St Value Rating: ★★★★★★
Overview: RaySearch Laboratories AB (publ) is a medical technology company that offers software solutions for cancer treatment globally, with a market capitalization of SEK6.19 billion.
Operations: RaySearch Laboratories generates revenue primarily from its healthcare software segment, which reported SEK1.27 billion.
RaySearch Laboratories, a nimble player in the medical technology space, is making waves with its innovative cancer treatment software. The company boasts no debt and trades at 46% below estimated fair value, offering potential upside for investors. Recent earnings showed a net income of SEK 19.6 million for Q2 2026, down from SEK 30.8 million the previous year. Despite this dip, RaySearch's earnings grew by 10% over the past year and outpaced industry growth rates of about 4%. Its strategic partnerships and AI-driven solutions are likely to bolster future revenue streams significantly.
innoscripta (XTRA:1INN)
Simply Wall St Value Rating: ★★★★★☆
Overview: innoscripta SE offers software-as-a-service solutions for managing R&D tax incentives and project management consulting across Germany, France, and the United Kingdom, with a market capitalization of €381 million.
Operations: With revenue of €122.41 million from its Internet Software & Services segment, innoscripta SE focuses on software-as-a-service solutions related to R&D tax incentives and project management consulting.
Innoscripta, a promising player in the software industry, has demonstrated impressive growth with earnings surging by 51% over the past year, surpassing the industry's 21.6%. The company trades at 84% below its estimated fair value and boasts strong cash flow, with levered free cash flow reaching €40.64 million by December 2025. Recent expansions into the UK and US markets have secured new clients like a New York-based tech group and a Minnesota clinical trial software provider. For 2026, Innoscripta anticipates revenue of at least €140 million and EBIT of €80 million, reflecting robust business momentum.
- Take a closer look at innoscripta's potential here in our health report.
Explore historical data to track innoscripta's performance over time in our Past section.
Make It Happen
- Gain an insight into the universe of 44 European Undiscovered Gems With Strong Fundamentals by clicking here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com